Feds Reschedule Approved Marijuana Products to Schedule III

On April 23, 2026, the U.S. Department of Justice and the Drug Enforcement Administration announced the immediate rescheduling of FDA-approved products containing marijuana and marijuana products regulated by a state medical license to Schedule III from Schedule I. It was also announced that an expedited administrative hearing process has been initiated to consider the rescheduling of marijuana to Schedule III to Schedule I. That hearing will now commence on June 29, 2026.

Acting U.S. Attorney General Todd Blanche stated that the rescheduling action “allows for research on the safety and efficacy of [marijuana], ultimately providing patients with better care and doctors with more reliable information.” The move neither legalized nor decriminalized under federal law the rescheduled substances.

Schedule I is the strictest classification and includes drugs that have a high potential for abuse and the potential to create severe psychological and/or physical dependence. Other Schedule I drugs include heroin, LSD and ecstasy. Schedule III drugs are those with a moderate to low potential for physical and psychological dependence. Among the drugs classified as Schedule III are ketamine, anabolic steroids and Tylenol with codeine.

Read the order and supporting documentation here.